On March 11, 2021 Redx Pharma reported a secured £3.9 million in funding from investors, including Alderley Park Ventures and BioCity (Press release, Redx Pharma, MAR 11, 2021, View Source [SID1234576479]). The funding marked a major milestone for KScan, its next-generation biomarker and molecular diagnostics platform for treating cancer patients and other conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Redx Pharma’s Lisa Anson talked about the company’s multi-million global licensing deal with pharma giant AstraZeneca, which will further develop and commercialise its treatment for sufferers of fibrotic diseases, and its other recent fundraising milestones.

The episode also heard Dr Kath Mackay discuss Alderley Park’s business support programme the Alderley Park Accelerator, which mentors companies through the investment process, and showcase why creating connections is so important.

Alderley Park, a development by Bruntwood SciTech, is the UK’s largest single-site life science campus and offers bioscience facilities for R&D-focussed life science companies at every stage of their lifecycle, from start-up to global corporate.

Episode two of its podcast looked at why university connections are vital for a life science and tech cluster like Alderley Park and how the campus works to inspire the next generation of scientists.

Meanwhile, the first episode focused on the challenges of rapidly building capacity for thousands of COVID tests at the Alderley Park Lighthouse Lab.